Which methods to choose to correct cell types in genome-scale blood-derived DNA methylation data?

Background High throughput methods such as microarray and DNA-methylation are used to measure the transcriptional variation due to exposures, treatments, phenotypes or clinical outcomes in whole blood, which could be confounded by the cellular heterogeneity [1,2]. Several algorithms have been developed to measure this cellular heterogeneity. However, it is unknown whether these approaches are consistent, and if not, which method(s) perform better.